ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema

PURPOSE: To evaluate the real-world effectiveness of intravitreal ranibizumab 0.5 mg (Lucentis) in improving visual acuity (VA) in adults with decreased VA due to diabetic macular edema (DME). PATIENTS AND METHODS: Real-world prospective observational 24-month study. Ranibizumab-naïve patients (n=11...

Descripción completa

Detalles Bibliográficos
Autores principales: Kodjikian, Laurent, Lecleire-Collet, Amélie, Dot, Corinne, Le Lez, Marie-Laure, Baillif, Stéphanie, Erginay, Ali, Souied, Eric, Fourmaux, Eric, Gain, Philippe, Ponthieux, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185131/
https://www.ncbi.nlm.nih.gov/pubmed/34113074
http://dx.doi.org/10.2147/OPTH.S313081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185131/
https://www.ncbi.nlm.nih.gov/pubmed/34113074
http://dx.doi.org/10.2147/OPTH.S313081

Ejemplares similares